

Deferred registration: NRG5051-102

Submission date 18/08/2026	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 20/08/2026	Overall study status Deferred	☐ Statistical analysis plan
		☐ Results
Last Edited 20/08/2026	Condition category Nervous System Diseases	☐ Individual participant data
		☒ Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Contact information

Type(s)

Principal investigator, Public, Scientific

Contact name

Dr Tunde Adebayo

Contact details

Parexel EPCU, Level 7, Northwick Park Hospital, Watford Road, Harrow
London
United Kingdom
HA1 3UJ
+44 1895 694883
harrowvolunteerfeedback@parexel.com

Additional identifiers

Integrated Research Application System (IRAS)

1014055

Parexel study code

297147

Study information

Scientific Title

Deferred registration: NRG5051-102 [Full scientific/public title to be added on or before the deferral expiry date]

Study objectives

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/07/2026, London Brent Research Ethics Committee (REC) (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; brent.rec@hra.nhs.uk), ref: 26/LO/0351

Primary study design

Interventional

Allocation

Non-randomized controlled trial

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Single

Purpose

biodistribution assessment, safety

Study type(s)**Health condition(s) or problem(s) studied**

Assessment of blood/brain distribution of an IMP for Neurodegenerative Disease, specifically ALS (Amyotrophic Lateral Sclerosis) in healthy adults

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Primary outcome(s)

1. [Outcome] measured using [measure] at [timepoint]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Key secondary outcome(s)**Completion date**

30/11/2026

Eligibility

Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Healthy volunteers allowed

Yes

Age group

Adult

Lower age limit

25 Years

Upper age limit

55 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date

Date of first enrolment

04/08/2026

Date of final enrolment

30/09/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre**Parexel EPCU (Early Phase Clinical Unit)**

Parexel, Level 7, Northwick Park Hospital, Watford Road, Harrow
London
England
HA1 3UJ

Sponsor information

Organisation

NRG Therapeutics Ltd

Funder(s)

Funder type**Funder Name**

NRG Therapeutics Ltd

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not expected to be made available